Elite Pharmaceuticals Releases Positive Top Line Human Abuse Liability Data for ELI-200, an Opioid Abuse Deterrent Product
September 09, 2014 07:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today reported top line results from a Human Abuse Liability (HAL) study for the...
Elite Pharmaceuticals to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
September 03, 2014 13:47 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP) a specialty pharmaceutical company developing a pipeline of pharmacological abuse deterrent opioids with...
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2015
August 14, 2014 16:14 ET
|
Elite Pharmaceuticals, Inc.
Revenues Increase by 61%, Product Development on Schedule
Conference Call Scheduled for Monday, August 18th at 11:00 AM EDT
NORTHVALE, N.J., Aug. 14, 2014 (GLOBE NEWSWIRE) -- Elite...
Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on August 18, 2014
August 13, 2014 07:09 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 13, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing...
Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for ELI-201
July 15, 2014 10:31 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., July 15, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in healthy...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2014
June 30, 2014 14:05 ET
|
Elite Pharmaceuticals, Inc.
Revenues Increase by 35%, Product Development Accelerating
Conference Call Scheduled for Tuesday, July 1 at 12:00 PM EDT
NORTHVALE, N.J., June 30, 2014 (GLOBE NEWSWIRE) -- Elite...
Elite Pharmaceuticals, Inc. to Host 2014 Fiscal Year End Conference Call on Tuesday, July 1, 2014
June 26, 2014 10:35 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 26, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing...
Elite Pharmaceuticals Enters Into $5 Million Settlement Agreement With Novel Laboratories
June 10, 2014 11:11 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 10, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) entered into a settlement agreement with Novel Laboratories, Inc. ("Novel"),...
Elite Pharmaceuticals Begins Human Abuse Liability Studies for ELI-200
June 09, 2014 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 9, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced dosing of the first subject in the treatment phase for a human...
Elite Pharmaceuticals Announces Results of 2014 Annual Meeting of Shareholders
May 23, 2014 11:08 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 23, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) today announced the voting results of matters considered during the...